Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Lancet

• Publication date

  2009-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(09)60442-6PMID 19249634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Seizures in multiple sclerosis

  2008cited by this paper
• Dose comparison trial of sustained-release fampridine in multiple sclerosis

  2008cited by this paper
• Walking capacities in multiple sclerosis measured by global positioning system odometer

  2007cited by this paper
• Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study

  2007cited by this paper
• Breast cancer at site of implanted vagus nerve stimulator

  2007cited by this paper
• Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.

  2006cited by this paper
• Short-distance walking speed and timed walking distance: Redundant measures for clinical trials?

  2006cited by this paper
• Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

  2006cited by this paper
• Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.

  2004cited by this paper
• Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.

  2004cited by this paper
• Carolinas Medical Center

  2004cited by this paper
• Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

  2003cited by this paper
• Measuring the impact of MS on walking ability

  2003cited by this paper
• Aminopyridines for symptomatic treatment in multiple sclerosis.

  2002cited by this paper
• Quantitative functional measures in MS: What is a reliable change?

  2002cited by this paper
• Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter

  2001cited by this paper
• Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

  2001cited by this paper
• Aminopyridines for symptomatic treatment in multiple sclerosis.

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Intrarater and interrater reliability of the MS functional composite outcome measure

  2000cited by this paper
• The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite

  2000cited by this paper
• The measurement of ambulatory impairment in multiple sclerosis

  1997cited by this paper
• Quantitative assessment of sustained‐release 4‐aminopyridine for symptomatic treatment of multiple sclerosis

  1997cited by this paper
• The effects of 4‐aminopyridine in multiple sclerosis patients

  1994cited by this paper
• The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis.

  1993cited by this paper
• The effect of 4‐aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo‐controlled, double‐blind, cross‐over study

  1992cited by this paper
• 4‐Aminopyridine in multiple sclerosis

  1991cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper
• Aminopyridines and similarly acting drugs : effects on nerves, muscles, and synapses : proceedings of a IUPHAR satellite symposium in conjunction with the 8th International Congress of Pharmacology, Paris, France, July 27-29, 1981

  1982cited by this paper
• PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

  1964cited by this paper

• The effects of fampridine on MS-related fatigue: a systematic review

  2026cites this paper
• Translational molecular imaging and drug development in multiple sclerosis

  2026cites this paper
• "Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center".

  2025cites this paper
• Efficacy and safety of 4-aminopyridine in episodic ataxia type 2: a case series

  2025cites this paper
• Voltage gating and 4-aminopyridine inhibition in the Shaker Kv channel revealed by a closed-state model

  2025cites this paper
• Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis

  2025cites this paper
• First evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions

  2025influential citation
• Real‐World Experience of Sustained‐Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue

  2025cites this paper
• Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders

  2025cites this paper
• Co-Highly Expressed SLC17A9 and KCNH1 as Potential Prognostic Biomarkers and Therapeutic Targets in Clear Cell Renal Cell Carcinoma.

  2025cites this paper
• Efficacy of caffeine supplementation on fatigue in patients with multiple sclerosis: A randomized double-blind placebo-controlled trial.

  2025cites this paper
• Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy

  2025cites this paper
• The effect of fampridine on working memory: a randomized controlled trial based on a genome-guided repurposing approach

  2024cites this paper
• Exploring the Versatility of 4-Aminopyridine and Its Analogues in Managing Demyelinating Diseases (A Review)

  2024cites this paper
• Effects of walking interventions in persons with multiple sclerosis-A systematic review.

  2024cites this paper
• Radiosynthesis automation, non-human primate biodistribution and dosimetry of K+ channel tracer [11C]3MeO4AP

  2024cites this paper
• Synthesis of K+ channel radioligand [18F]5-methyl-3-fluoro-4-aminopyridine and PET imaging in mice

  2024cites this paper
• Progression of axonal excitability abnormalities with increasing clinical severity of diabetic peripheral neuropathy.

  2024cites this paper
• Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis.

  2024cites this paper
• Targeting ion channels with ultra-large library screening for hit discovery

  2024cites this paper
• Chemical and biophysical characterization of novel potassium channel blocker 3-fluoro-5-methylpyridin-4-amine

  2024cites this paper
• Regression Analyses and Their Particularities in Observational Studies—Part 32 of a Series on Evaluation of Scientific Publications.

  2024cites this paper
• Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with multiple sclerosis.

  2024cites this paper
• Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study

  2024cites this paper
• Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial

  2024cites this paper
• Structural Basis for Voltage Gating and Dalfampridine Binding in the Shaker Potassium Channel

  2024cites this paper
• Enhancing the understanding of abstract neurophysiology concepts by first-year students at the University of La Réunion.

  2024cites this paper
• Quality of reporting health behaviors for multiple sclerosis (QuoRH‐MS): A scoping review to inform intervention planning and improve consistency of reporting

  2024cites this paper
• Providing meaningful interpretation of performance outcome measures by co-calibration with patient-reported outcomes through the Rasch model: illustration with multiple sclerosis measures

  2023cites this paper
• Chemical and biophysical characterization of novel potassium channel blocker 3-fluoro-5-methylpyridin-4-amine

  2023cites this paper
• The six spot step test is superior in detecting walking capacity impairments compared to short- and long-distance walk tests in persons with multiple sclerosis

  2023cites this paper
• Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis

  2023cites this paper
• Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system

  2023cites this paper
• Radiosynthesis automation, non-human primate biodistribution and dosimetry of K+ channel tracer [11C]3MeO4AP

  2023cites this paper
• Recommendations on the Selection, Development, and Modification of Performance Outcome Assessments: A Good Practices Report of an ISPOR Task Force.

  2023cites this paper
• Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection.

  2023cites this paper
• The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial

  2022cites this paper
• Cost-effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China.

  2022cites this paper
• Gait quality and function after fampridine treatment in patients with multiple sclerosis - A prospective cohort study.

  2022cites this paper
• Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP

  2022cites this paper
• Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.

  2022cites this paper
• Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE

  2022cites this paper
• Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study

  2022cites this paper
• Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2

  2022cites this paper
• Amifampridine Phosphate (Firdapse)

  2022cites this paper
• Intensive Neurorehabilitation and Gait Improvement in Progressive Multiple Sclerosis: Clinical, Kinematic and Electromyographic Analysis

  2022cites this paper
• Roles of voltage-gated potassium channels in the maintenance of pancreatic cancer stem cells

  2021cites this paper
• A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

  2021cites this paper
• High-dose biotin for multiple sclerosis: A systematic review and meta-analyses of randomized controlled trials.

  2021cites this paper
• H/D Exchange for 4-Aminopyridine: Application on MAO in Sera of Multiple Sclerosis Patients

  2021cites this paper
• Clinical, Neurophysiological, and MRI Markers of Fampridine Responsiveness in Multiple Sclerosis—An Explorative Study

  2021cites this paper
• Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden

  2021cites this paper
• Postural stability is a valid and meaningful disability metric in progressive MS with potential for use in neuroprotective therapy trials.

  2021cites this paper
• Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial

  2021cites this paper
• Community qigong for People with Multiple Sclerosis: A Pragmatic Feasibility Study

  2021cites this paper
• Unsupervised behaviour analysis and magnification (uBAM) using deep learning

  2021cites this paper
• Comparison of K+ Channel Families.

  2021cites this paper
• Gait quality and function in patients with Multiple Scleroses following Fampridine treatment

  2021cites this paper
• Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study

  2021cites this paper
• Neuroprotective Properties of 4-Aminopyridine

  2021cites this paper
• Mind the gap: from neurons to networks to outcomes in multiple sclerosis

  2021cites this paper
• Treating MS After 50: the Role of Age in Therapeutic Decision-Making

  2021cites this paper
• Approach to the Patient with Gait Disturbance.

  2021cites this paper
• Symptom Management in Multiple Sclerosis

  2021cites this paper
• Multiple Sklerose: Therapie

  2020cites this paper
• Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis.

  2020cites this paper
• Cortical projection neurons as a therapeutic target in multiple sclerosis

  2020cites this paper
• Potential of Timed 25-Foot Walk Values in Predicting Maximum Walking Distance in Persons with Multiple Sclerosis.

  2020cites this paper
• Pharmakologische Behandlung der multiplen Sklerose

  2020cites this paper
• Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies

  2020cites this paper
• Dalfampridine benefits ambulation but not cognition in multiple sclerosis

  2020cites this paper
• uBAM: Unsupervised Behavior Analysis and Magnification using Deep Learning

  2020cites this paper
• Wilhelm Uhthoff and Uhthoff’s phenomenon

  2020cites this paper
• Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.

  2020cites this paper
• [Efficacy and safety of Kinezia (fampridine) in the complex therapy of multiple sclerosis].

  2020cites this paper
• Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.

  2020cites this paper
• The effect of fampridine on the risk of seizure in patients with multiple sclerosis.

  2020cites this paper
• 4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes

  2020cites this paper
• HPLC method development for fampridine using Analytical Quality by Design approach

  2020cites this paper
• Can Operant Conditioning of EMG-Evoked Responses Help to Target Corticospinal Plasticity for Improving Motor Function in People With Multiple Sclerosis?

  2020cites this paper
• Mechanisms of Genome Protection and Repair

  2020cites this paper
• Unleashing the Promise of Biotechnology to Help Heal, Fuel, and Feed the World

  2020cites this paper
• Mystery of Expansion: DNA Metabolism and Unstable Repeats.

  2020cites this paper
• Clinical assessment, management and rehabilitation of walking impairment in MS: An Expert Review.

  2020cites this paper
• Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.

  2020cites this paper
• Effects of robot-assisted gait training combined with virtual reality on motor and cognitive functions in patients with multiple sclerosis: A pilot, single-blind, randomized controlled trial

  2020cites this paper
• Fampridine and Acetazolamide in EA2 and Related Familial EA

  2020influential citation
• Evaluation of the potassium channel tracer [18F]3F4AP in rhesus macaques

  2020cites this paper
• Efficacy and safety of fampridine for walking disability in multiple sclerosis.

  2020cites this paper
• Immunmediierte Erkrankungen des Nervensystems

  2020cites this paper
• Hypsarrhythmia and spasms resolution after Valproic acid discontinuation in an infantile spasm patient

  2019cites this paper
• Hashimoto’s Encephalopathy Presenting with Progressive Cerebellar Ataxia

  2019cites this paper
• Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

  2019cites this paper
• Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial

  2019cites this paper
• Cortical Excitability Measures May Predict Clinical Response to Fampridine in Patients with Multiple Sclerosis and Gait Impairment

  2019cites this paper
• Gait tests in multiple sclerosis: Reliability and cut-off values.

  2019cites this paper
• Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS

  2019cites this paper
• Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis

  2019cites this paper
• The Role of Fampridine in the Symptomatic Treatment of Gait Impairment in Patients with Multiple Sclerosis

  2019cites this paper
• Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis

  2019cites this paper